Koji Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Koji Kato has a total of 570 co-authors. Here are the top co-authors by number of shared publications:
Koichi Akashi
24 shared publicationsKohta Miyawaki
Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
13 shared publications- Koichi Akashi
Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, Fukuoka, Japan
13 shared publications - Toshihiro Miyamoto
Department of Hematology, Faculty of Medicine Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan
12 shared publications Yasuo Mori
11 shared publicationsGoichi Yoshimoto
10 shared publications
Latest Publications
- Open Access
- 11 October 2026
- Published by Wiley in Cancer Science
Angiogenic and Stromal Remodeling Associated With Aggressive Fibrosarcomatous Dermatofibrosarcoma Protuberans
Although collagen type 1 alpha 1 ( COL1A1 )–platelet‐derived growth factor B‐chain ( PDGFB ) gene fusion is a characteristic driver alteration in fibrosarcomatous dermatofibrosarcoma protuberans (FS‐DFSP), an aggressive DFSP variant, the tumor microenvironment (TME) underlying the aggressive phenotype remains unclear. We investigated microenvironmental and molecular differences between pure‐DFSP and FS‐DFSP using integrated histopathologic and transcriptomic analyses of archival samples from 122 patients, including 39 with FS‐DFSP. Histopathologic evaluation, immunohistochemistry, and transcriptomic analyses were performed to assess vascular features, cancer‐associated fibroblasts (CAFs), macrophage infiltration, and angiogenesis‐related molecular alterations. FS‐DFSP demonstrated increased CD31‐positive vascular structures without a corresponding increase in αSMA‐positive vascular structures, suggesting immature vascular features. CAF markers, including periostin and fibroblast activation protein, were significantly upregulated in intratumoral and invasive front regions of FS‐DFSP. Gene expression analysis was performed separately for the fibrosarcomatous and DFSP components of the FS‐DFSP cases and for the pure‐DFSP cases. By targeted transcriptomic profiling, the DFSP and fibrosarcomatous components within the FS‐DFSP cases shared molecular features, suggesting early tumor microenvironment‐associated alterations that preceded overt fibrosarcomatous morphology. Integrated transcriptomic and protein analyses revealed upregulation of angiogenesis‐related molecules, including vascular endothelial growth factor A (VEGFA), C‐C motif chemokine ligand 2 (CCL2), and C‐X‐C motif chemokine receptor 4 (CXCR4) in FS‐DFSP. Periostin‐positive CAFs coexpressed VEGFA and CCL2, potentially contributing to angiogenic features within the tumor microenvironment. These findings reveal that FS‐DFSP is characterized by coordinated angiogenic and stromal remodeling involving tumor cells and CAFs and suggest that the tumor microenvironment may represent a potential focus for future therapeutic investigation.
- 11 October 2026
- Published by Wiley in Cancer Science
Open AccessAngiogenic and Stromal Remodeling Associated With Aggressive Fibrosarcomatous Dermatofibrosarcoma Protuberans
Although collagen type 1 alpha 1 ( COL1A1 )–platelet‐derived growth factor B‐chain ( PDGFB ) gene fusion is a characteristic driver alteration in fibrosarcomatous dermatofibrosarcoma protuberans (FS‐DFSP), an aggressive DFSP variant, the tumor microenvironment (TME) underlying the aggressive phenotype remains unclear. We investigated microenvironmental and molecular differences between pure‐DFSP and FS‐DFSP using integrated histopathologic and transcriptomic analyses of archival samples from 122 patients, including 39 with FS‐DFSP. Histopathologic evaluation, immunohistochemistry, and transcriptomic analyses were performed to assess vascular features, cancer‐associated fibroblasts (CAFs), macrophage infiltration, and angiogenesis‐related molecular alterations. FS‐DFSP demonstrated increased CD31‐positive vascular structures without a corresponding increase in αSMA‐positive vascular structures, suggesting immature vascular features. CAF markers, including periostin and fibroblast activation protein, were significantly upregulated in intratumoral and invasive front regions of FS‐DFSP. Gene expression analysis was performed separately for the fibrosarcomatous and DFSP components of the FS‐DFSP cases and for the pure‐DFSP cases. By targeted transcriptomic profiling, the DFSP and fibrosarcomatous components within the FS‐DFSP cases shared molecular features, suggesting early tumor microenvironment‐associated alterations that preceded overt fibrosarcomatous morphology. Integrated transcriptomic and protein analyses revealed upregulation of angiogenesis‐related molecules, including vascular endothelial growth factor A (VEGFA), C‐C motif chemokine ligand 2 (CCL2), and C‐X‐C motif chemokine receptor 4 (CXCR4) in FS‐DFSP. Periostin‐positive CAFs coexpressed VEGFA and CCL2, potentially contributing to angiogenic features within the tumor microenvironment. These findings reveal that FS‐DFSP is characterized by coordinated angiogenic and stromal remodeling involving tumor cells and CAFs and suggest that the tumor microenvironment may represent a potential focus for future therapeutic investigation.
- Open Access
- 12 August 2026
- Published by Wiley in Cancer Science
- Vol. 117 (11) , 3108-3120
Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3 ‐ ITD –Positive AML
Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication ( FLT3 ‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3 ‐ITD–positive AML. This multicenter, single‐arm study in Japan (jRCTs071200015) enrolled 18 patients between May 2020 and December 2022. Of these, 15 patients received oral quizartinib (up to 53 mg once daily) for up to 12 cycles of 28 days each, then were followed for 12 months. The primary endpoint was to evaluate the type and rate of quizartinib resistance mutations; secondary endpoints included composite complete remission (CRc) rate, overall response rate (ORR), hematopoietic stem cell transplantation (HSCT) rate, relapse‐free survival (RFS), overall survival (OS), and adverse events (AEs). Among seven evaluable patients, acquired mutations were detected in four patients ( NF1 [R2616X], CSF3R [Q754X], NRAS [G13R], and FLT3 [D835Y] in one patient each), while loss of FLT3 ‐ITD was observed in two patients. In efficacy analyses ( n = 15), CRc rate was 66.7% (95% confidence interval [CI], 38.4–88.2), ORR was 73.3% (44.9–92.2), and median OS was 13.6 months (5.4–not evaluable). Three patients (20.0%) received HSCT directly after quizartinib; in these patients, median RFS was 8.5 months (95% CI, 6.2–not evaluable). Grade ≥ 3 non‐hematologic AEs and grade 1 QT prolongation were each reported in three patients (20.0%). These data offer additional information on potential resistance mechanisms in patients with relapsed or refractory FLT3 ‐ITD–positive AML. Trial Registration: Japan Registry of Clinical Trials (jRCTs071200015).
- 12 August 2026
- Published by Wiley in Cancer Science
- Vol. 117 (11) , 3108-3120
Open AccessQuizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3 ‐ ITD –Positive AML
Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication ( FLT3 ‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3 ‐ITD–positive AML. This multicenter, single‐arm study in Japan (jRCTs071200015) enrolled 18 patients between May 2020 and December 2022. Of these, 15 patients received oral quizartinib (up to 53 mg once daily) for up to 12 cycles of 28 days each, then were followed for 12 months. The primary endpoint was to evaluate the type and rate of quizartinib resistance mutations; secondary endpoints included composite complete remission (CRc) rate, overall response rate (ORR), hematopoietic stem cell transplantation (HSCT) rate, relapse‐free survival (RFS), overall survival (OS), and adverse events (AEs). Among seven evaluable patients, acquired mutations were detected in four patients ( NF1 [R2616X], CSF3R [Q754X], NRAS [G13R], and FLT3 [D835Y] in one patient each), while loss of FLT3 ‐ITD was observed in two patients. In efficacy analyses ( n = 15), CRc rate was 66.7% (95% confidence interval [CI], 38.4–88.2), ORR was 73.3% (44.9–92.2), and median OS was 13.6 months (5.4–not evaluable). Three patients (20.0%) received HSCT directly after quizartinib; in these patients, median RFS was 8.5 months (95% CI, 6.2–not evaluable). Grade ≥ 3 non‐hematologic AEs and grade 1 QT prolongation were each reported in three patients (20.0%). These data offer additional information on potential resistance mechanisms in patients with relapsed or refractory FLT3 ‐ITD–positive AML. Trial Registration: Japan Registry of Clinical Trials (jRCTs071200015).
- Open Access
- 24 July 2026
- Published by Wiley in Cancer Science
- Vol. 117 (11) , 3098-3107
Real‐World Safety and Efficacy of Pola‐R‐ CHP in Previously Untreated DLBCL : POLASTAR Interim Analysis of 500 Patients
POLASTAR (jRCT1071220082) is a multicenter, prospective observational study evaluating the real‐world efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola‐R‐CHP) in Japanese patients with diffuse large B‐cell lymphoma (DLBCL), addressing the limited real‐world data in this setting. Patients ≥ 18 years, with previously untreated DLBCL, receiving Pola‐R‐CHP were enrolled. Patients excluded from POLARIX (NCT03274492), including those > 80 years, were included. Overall, 485 patients were included in the full analysis set (FAS; median age, 71 years [range 27–93]; age ≤ 80 years, 87.6%; International Prognostic Index score 2–5, 73.7%). Median relative dose intensity (RDI) for rituximab and polatuzumab vedotin was ≥ 93.0% (both FAS and patients > 80 years), and for the chemotherapy components median RDI was ≥ 87.2% in the FAS and ≥ 49.6% for patients > 80 years. Grade ≥ 3 adverse events (AEs) occurred in 47.4% of patients in the FAS and 56.7% of patients > 80 years; serious AEs occurred in 12.6% and 25.0%, respectively. The most common Grade ≥ 3 AE (FAS/> 80 years) was neutrophil count decreased (25.6%/26.7%). In the FAS, 5 (1.0%) deaths due to AEs were reported and 33 (6.8%) patients discontinued polatuzumab vedotin due to AEs. No new safety signals were observed. In the FAS, overall response rate and complete response rate (95% confidence interval [CI]) were 93.2% (90.5–95.2) and 83.3% (79.6–86.5), respectively, and were 87.3% (76.0–93.7) and 80.0% (67.6–88.4) in patients > 80 years. Safety and efficacy of Pola‐R‐CHP in Japanese patients, including those > 80 years, were consistent with results from POLARIX. Trial Registration: Japan Registry of Clinical Trials (jRCT1071220082)
- 24 July 2026
- Published by Wiley in Cancer Science
- Vol. 117 (11) , 3098-3107
Open AccessReal‐World Safety and Efficacy of Pola‐R‐ CHP in Previously Untreated DLBCL : POLASTAR Interim Analysis of 500 Patients
POLASTAR (jRCT1071220082) is a multicenter, prospective observational study evaluating the real‐world efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola‐R‐CHP) in Japanese patients with diffuse large B‐cell lymphoma (DLBCL), addressing the limited real‐world data in this setting. Patients ≥ 18 years, with previously untreated DLBCL, receiving Pola‐R‐CHP were enrolled. Patients excluded from POLARIX (NCT03274492), including those > 80 years, were included. Overall, 485 patients were included in the full analysis set (FAS; median age, 71 years [range 27–93]; age ≤ 80 years, 87.6%; International Prognostic Index score 2–5, 73.7%). Median relative dose intensity (RDI) for rituximab and polatuzumab vedotin was ≥ 93.0% (both FAS and patients > 80 years), and for the chemotherapy components median RDI was ≥ 87.2% in the FAS and ≥ 49.6% for patients > 80 years. Grade ≥ 3 adverse events (AEs) occurred in 47.4% of patients in the FAS and 56.7% of patients > 80 years; serious AEs occurred in 12.6% and 25.0%, respectively. The most common Grade ≥ 3 AE (FAS/> 80 years) was neutrophil count decreased (25.6%/26.7%). In the FAS, 5 (1.0%) deaths due to AEs were reported and 33 (6.8%) patients discontinued polatuzumab vedotin due to AEs. No new safety signals were observed. In the FAS, overall response rate and complete response rate (95% confidence interval [CI]) were 93.2% (90.5–95.2) and 83.3% (79.6–86.5), respectively, and were 87.3% (76.0–93.7) and 80.0% (67.6–88.4) in patients > 80 years. Safety and efficacy of Pola‐R‐CHP in Japanese patients, including those > 80 years, were consistent with results from POLARIX. Trial Registration: Japan Registry of Clinical Trials (jRCT1071220082)
- 23 July 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (5) , 661-669
Early prediction of ICANS using CRS characteristics in B-cell lymphoma patients receiving CAR-T therapy
- 23 July 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (5) , 661-669
Early prediction of ICANS using CRS characteristics in B-cell lymphoma patients receiving CAR-T therapy
- Open Access
- 23 April 2026
- Published by Springer Nature in Research Square
Direct Flow Cytometric Assessment of Cerebrospinal Fluid CAR-T Cells for ICANS Diagnosis
Diagnosing immune effector cell-associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR)-T cell therapy remains challenging due to the lack of objective, specific biomarkers. We analyzed cerebrospinal fluid (CSF) samples collected at neurological symptom onset from 24 patients following CD19-targeted CAR-T therapy including 18 with ICANS requiring steroid treatment and 6 without ICANS who had alternative neurological diagnoses or self-limiting symptoms. Multicolor flow cytometry identified CAR-T cells as CD3⁺ FMC63⁺ lymphocytes. The proportion of CAR-T cells within CD3⁺ T cells was significantly higher in ICANS patients than in non-ICANS patients (median 32.3% vs. 7.9%, p = 0.018), with a predominance of CD4⁺ T cells. Receiver operating characteristic analysis identified a diagnostic cutoff of ≥20%, achieving a sensitivity of 0.72 and a specificity of 0.83 (AUC 0.80). Combining this CSF parameter with peripheral blood markers such as fibrinogen or CRS grade further improved diagnostic accuracy, suggesting that CSF-derived parameters reflecting the local immune environment at the site of pathology complement systemic markers in the diagnostic evaluation of ICANS. These findings indicate that flow cytometric assessment of CAR-T cells in CSF, which uniquely allows proportional quantification within T-cell subsets, provides an objective diagnostic tool for ICANS requiring therapeutic intervention.
- 23 April 2026
- Published by Springer Nature in Research Square
Open AccessDirect Flow Cytometric Assessment of Cerebrospinal Fluid CAR-T Cells for ICANS Diagnosis
Diagnosing immune effector cell-associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR)-T cell therapy remains challenging due to the lack of objective, specific biomarkers. We analyzed cerebrospinal fluid (CSF) samples collected at neurological symptom onset from 24 patients following CD19-targeted CAR-T therapy including 18 with ICANS requiring steroid treatment and 6 without ICANS who had alternative neurological diagnoses or self-limiting symptoms. Multicolor flow cytometry identified CAR-T cells as CD3⁺ FMC63⁺ lymphocytes. The proportion of CAR-T cells within CD3⁺ T cells was significantly higher in ICANS patients than in non-ICANS patients (median 32.3% vs. 7.9%, p = 0.018), with a predominance of CD4⁺ T cells. Receiver operating characteristic analysis identified a diagnostic cutoff of ≥20%, achieving a sensitivity of 0.72 and a specificity of 0.83 (AUC 0.80). Combining this CSF parameter with peripheral blood markers such as fibrinogen or CRS grade further improved diagnostic accuracy, suggesting that CSF-derived parameters reflecting the local immune environment at the site of pathology complement systemic markers in the diagnostic evaluation of ICANS. These findings indicate that flow cytometric assessment of CAR-T cells in CSF, which uniquely allows proportional quantification within T-cell subsets, provides an objective diagnostic tool for ICANS requiring therapeutic intervention.
- Open Access
- 16 April 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Gene expression profile of adult T-cell leukemia/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia/lymphoma
- 16 April 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Open AccessGene expression profile of adult T-cell leukemia/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia/lymphoma
- 3 January 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (5) , 737-745
Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL
Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma characterized by 9p24.1 copy-number alterations and PD-1-mediated immune evasion. This profile confers high sensitivity to PD-1 inhibitors such as pembrolizumab. CD19-directed chimeric antigen receptor (CAR) T-cell therapies have shown benefit in relapsed or refractory (R/R) PMBCL, but their optimal role remains undefined. We retrospectively analyzed 31 patients with R/R B-cell lymphoma treated with lisocabtagene maraleucel (liso-cel), including four with PMBCL who received pembrolizumab prior to CAR-T. All four achieved remission before infusion, and three maintained durable complete responses (≥ 30 months). Toxicities were comparable to those in patients not treated with pembrolizumab, although one pembrolizumab-treated patient experienced fatal neurotoxicity. Favorable hematologic recovery and preserved T-cell counts at leukapheresis suggest that preceding PD-1 blockade did not compromise CAR-T manufacturing and may have enhanced T-cell fitness. These findings suggest that sequential PD-1 blockade followed by liso-cel is clinically feasible and may improve outcomes by leveraging the immune vulnerability of PMBCL. While prior studies have focused on axicabtagene ciloleucel, this report provides the first real-world data supporting the feasibility and potential benefit of this approach with liso-cel. Prospective studies are needed to confirm efficacy, safety, and optimal sequencing.
- 3 January 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (5) , 737-745
Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL
Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma characterized by 9p24.1 copy-number alterations and PD-1-mediated immune evasion. This profile confers high sensitivity to PD-1 inhibitors such as pembrolizumab. CD19-directed chimeric antigen receptor (CAR) T-cell therapies have shown benefit in relapsed or refractory (R/R) PMBCL, but their optimal role remains undefined. We retrospectively analyzed 31 patients with R/R B-cell lymphoma treated with lisocabtagene maraleucel (liso-cel), including four with PMBCL who received pembrolizumab prior to CAR-T. All four achieved remission before infusion, and three maintained durable complete responses (≥ 30 months). Toxicities were comparable to those in patients not treated with pembrolizumab, although one pembrolizumab-treated patient experienced fatal neurotoxicity. Favorable hematologic recovery and preserved T-cell counts at leukapheresis suggest that preceding PD-1 blockade did not compromise CAR-T manufacturing and may have enhanced T-cell fitness. These findings suggest that sequential PD-1 blockade followed by liso-cel is clinically feasible and may improve outcomes by leveraging the immune vulnerability of PMBCL. While prior studies have focused on axicabtagene ciloleucel, this report provides the first real-world data supporting the feasibility and potential benefit of this approach with liso-cel. Prospective studies are needed to confirm efficacy, safety, and optimal sequencing.